Postirradiation laryngeal osteosarcoma: Case report and literature review
โ Scribed by Tzung-Shiahn Sheen; Chen-Tu Wu; Ti Hsieh; Mow-Ming Hsu
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 454 KB
- Volume
- 19
- Category
- Article
- ISSN
- 1043-3074
No coin nor oath required. For personal study only.
โฆ Synopsis
Background:
Laryngeal sarcoma is a rare disease entity. in review of the literature, chondrosarcoma is the most common sarcoma, followed by fibrosarcoma. osteosarcoma is very rare; there are only seven cases reported in the literature. postirradiation sarcoma is a late complication of radiotherapy. osteosarcoma is the most common type in this group. the larynx is often involved in the radiation field of treatment for head and neck malignancies. however, postirradiation laryngeal osteosarcoma has not yet been reported.
Methods:
We present a 56-year-old man who under went radiotherapy for nasopharyngeal carcinoma 32 years ago and later developed a laryngeal osteosarcoma.
Results:
The patient underwent total laryngectomy but died 1 year and 9 months later with locally extensive disease.
Conclusions:
We report the first case of postirradiation laryngeal osteosarcoma. in addition to surgical treatment, adjunctive therapies should be considered for this group of patients.
๐ SIMILAR VOLUMES
Kimura's disease, which occurs endemically in the Far East and sporadically in the West, has so far eluded efforts to determine its exact pathogenesis. It presents as solitary or multiple benign swellings of the skin, has a predilection for the periauricular and scalp regions, and often is associate
Macrothrombocytopenias (MTCP) are a heterogeneous group of disorders associated with thrombocytopenia and giant platelets, and may include other clinical or laboratory findings such as hereditary nephritis, sensorineural deafness, leukocyte inclusions, and cataracts. Patients with MTCP may have mild
FL 33612 to permit rapid consideration for publication. ## Recurrent Lymphocytic Pleural Effusion After Intravenous Immunoglobulin To the Editor: A 35-year-old female was initially diagnosed in 1981 with stage IIA Hodgkin's disease treated successfully with MOPP (mechlorethamine, oncovin, procarb